McKesson extends CVS pact through 2032. CVS Health stock has results on November 4 2026
Published on 10/12/2026 at 11:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- McKesson agreed in principle on October 1, 2026, to extend its pharmaceutical distribution partnership with CVS Health through June 2032.
- CVS Health reported second-quarter 2026 revenue of USD 106.10 billion, up 7.30 percent year over year.
- The stock was at EUR 76.90 at Lang & Schwarz on October 12, 2026, versus the Xetra close of EUR 77.48 on October 9, 2026.
- CVS Health declared a quarterly dividend of USD 0.665 per share, with the record date on October 22, 2026.
CVS Health Corp. (US1266501006) was at EUR 76.90 at Lang & Schwarz in trading on October 12, 2026 at 10:58 a.m. CEST, down EUR 0.58, or 0.75 percent, versus the Xetra close of EUR 77.48 on October 9, 2026. The latest company-linked development is a distribution agreement in principle with McKesson running through June 2032, while CVS Health stock has its next results date set for November 4, 2026.
Three events shape the picture
On August 5, 2026, CVS Health reported second-quarter revenue of USD 106.10 billion, up 7.30 percent year over year. Ticker Scout also lists GAAP diluted earnings per share of USD 2.31, compared with USD 0.80 a year earlier, and adjusted earnings per share of USD 2.58 versus USD 1.81.
On September 30, 2026, CVS Health declared a quarterly dividend of USD 0.665 per share. The payment is scheduled for November 2, 2026, for holders of record on October 22, 2026.
On October 1, 2026, McKesson announced an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032, covering mail order, specialty and retail pharmacies, and distribution centers, FT reported. The arrangement is still subject to a definitive contract, and the source identified execution delays as a risk.
What does the earnings base show?
The second-quarter figures give the distribution agreement a measurable operating backdrop. Revenue increased from USD 98.90 billion in the prior-year quarter to USD 106.10 billion, while GAAP diluted earnings per share rose from USD 0.80 to USD 2.31. CVS Health also reported operating profit of USD 4.70 billion and operating cash flow of USD 6.35 billion for the quarter ended June 30, 2026.
Key dates for CVS Health
The next dated shareholder event is October 22, 2026, when the dividend record date arrives. The USD 0.665 per-share payment follows on November 2, 2026. CVS Health is scheduled to report third-quarter 2026 results on November 4, 2026, giving investors the next test of revenue growth, medical costs and cash generation.
Stock price and market value
The Lang & Schwarz price of EUR 76.90 on October 12, 2026 stood 0.75 percent below the Xetra close of EUR 77.48 on October 9, 2026. The primary-market context was a USD 86.16 last price for NYSE-listed CVS Health on October 9, 2026, with a USD 69.51 to USD 110.68 52-week range and market capitalization of USD 109.9 billion as of that date.
The further course of trading is shown by the continuously updated real-time quote of CVS Health stock.
CVS Health stock facts
- Company: CVS Health Corporation
- ISIN: US1266501006
- Ticker: CVS
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 12, 2026, 10:58 a.m. CEST): EUR 76.90
- Change versus Xetra close: minus 0.75 percent
- Xetra close (October 9, 2026): EUR 77.48
- Market capitalization: USD 109.9 billion (as of October 9, 2026)
- 52-week range: USD 69.51-110.68 (as of October 9, 2026)
- Sector / Industry: Health care / Health care providers and services
- Index membership: S&P 500
- Next earnings date: November 4, 2026
Market context: Market report S&P 500.
